Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Hackensack Meridian Health
Hackensack Meridian Health
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Amgen
Stanford University
Ipsen
University of Pennsylvania
Brown University
Fred Hutchinson Cancer Center
ADC Therapeutics S.A.
ADC Therapeutics S.A.
Fred Hutchinson Cancer Center
Gilead Sciences
Dartmouth-Hitchcock Medical Center
Massachusetts General Hospital
Pfizer
Ohio State University Comprehensive Cancer Center